Aurora Cannabis (TSE:ACB) Upgraded to Hold at BMO Capital Markets

BMO Capital Markets upgraded shares of Aurora Cannabis (TSE:ACB) to a hold rating in a report released on Wednesday morning,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. TD lowered their price objective on shares of Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating for the company in a research note on Friday, June 12th. Canaccord Genuity Group cut their target price on Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of C$7.17.

Aurora Cannabis Stock Down 0.5%

ACB stock opened at C$4.15 on Wednesday. The firm has a 50 day moving average of C$4.08 and a 200 day moving average of C$4.63. The stock has a market capitalization of C$257.06 million, a PE ratio of -1.94 and a beta of 0.25. The company has a quick ratio of 2.48, a current ratio of 5.36 and a debt-to-equity ratio of 4.30. Aurora Cannabis has a 52 week low of C$3.59 and a 52 week high of C$9.33.

Aurora Cannabis (TSE:ACB) last released its earnings results on Wednesday, August 5th. The company reported C($0.07) earnings per share for the quarter. Aurora Cannabis had a negative return on equity of 5.21% and a negative net margin of 9.53%.The company had revenue of C$67.55 million for the quarter. Sell-side analysts forecast that Aurora Cannabis will post -0.22 earnings per share for the current year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.